KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Accumulated Expenses (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Other Accumulated Expenses for 13 consecutive years, with $966000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 35.29% to $966000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $966000.0, a 35.29% increase, with the full-year FY2025 number at $966000.0, up 35.29% from a year prior.
  • Other Accumulated Expenses was $966000.0 for Q4 2025 at Xenon Pharmaceuticals, up from $935000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.1 million in Q2 2024 to a low of $26000.0 in Q3 2021.
  • A 5-year average of $418842.1 and a median of $282000.0 in 2022 define the central range for Other Accumulated Expenses.
  • Biggest YoY gain for Other Accumulated Expenses was 1106.59% in 2024; the steepest drop was 86.13% in 2024.
  • Xenon Pharmaceuticals' Other Accumulated Expenses stood at $118000.0 in 2021, then skyrocketed by 188.98% to $341000.0 in 2022, then crashed by 68.62% to $107000.0 in 2023, then soared by 567.29% to $714000.0 in 2024, then soared by 35.29% to $966000.0 in 2025.
  • Per Business Quant, the three most recent readings for XENE's Other Accumulated Expenses are $966000.0 (Q4 2025), $935000.0 (Q3 2025), and $439000.0 (Q2 2025).